CPC A61K 31/529 (2013.01) [A61K 31/44 (2013.01); A61K 31/454 (2013.01); A61K 31/495 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61K 38/07 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] | 8 Claims |
1. A method of treating a patient having cancer, the method comprising administering to the patient a therapeutically effective amount of (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene and radiotherapy, wherein MYC overexpression, MCL1 overexpression, or MYC and MCL1 overexpression is differentially present in a biological sample taken from the patient as compared with a biological sample taken from a subject of another phenotypic status.
|